Dermata Therapeutics Inc (DRMA) Stock Price, Quote & News

Company Profile

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 800 2543

Website: www.dermatarx.com

Address:

3525 Del Mar Heights Rd., Suite 332, San Diego, United States

Guestthatrader Apr. 4 at 6:07 PM

$DRMA where everyone at check in

0 · Reply

focafoca99 Apr. 2 at 7:52 PM

$DRMA Australia accepted its patent application covering the use of its Bioneedle Delivery System with topical dermal fillers.

0 · Reply

brallt Apr. 2 at 1:11 PM

$DRMA 👀 Another step in the right direction to product release. Buy the Rumor Sell the News.

0 · Reply

David_M_ Apr. 2 at 12:40 PM

$DRMA https://www.stocktitan.net/news/DRMA/dermata-receives-notice-of-acceptance-of-australian-patent-wz0p6wyu8dva.html

0 · Reply

Stock_Catcher Apr. 2 at 12:30 PM

$DRMA Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System

0 · Reply

brallt Apr. 1 at 1:48 PM

$DRMA Revenue generated by the release of a skin care product that retail does not have to jump through hoops to get will generate a positive fundemental shift with this company. If you knew that you would make 100% within 3months time. How many shares would you Buy?

0 · Reply

SwingNow Apr. 1 at 1:06 PM

$DRMA is under naked shorting by Maxim group, the moment it break the dt they came out lowering target price

0 · Reply

Guestthatrader Mar. 31 at 7:10 PM

$DRMA one of these things is imminent acquisition partnership licensing agreements or strait buy outright not hype rumors just facts

1 · Reply

Guestthatrader Mar. 31 at 12:08 PM

$DRMA this is severely undervalued should not be trading like this

1 · Reply

Guestthatrader Mar. 31 at 2:28 AM

$DRMA with volume this can actually squeeze the shorts if not this becomes a liquidity trap…. The earnings report is still bullish we have a recent insider buy we got bullish news and patent …. Let’s go bulls

0 · Reply

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System

Mar 26, 2026, 5:15 PM EDT - 9 days ago

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025

Mar 20, 2026, 10:39 AM EDT - 15 days ago

Dermata Shares Rise After USPTO Issues Patent Notice Of Allowance

Mar 10, 2026, 8:30 AM EDT - 25 days ago

Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing

Mar 5, 2026, 9:00 AM EST - 4 weeks ago

Dermata Opens a New Chapter with the Release of Tome Skincare

Jan 20, 2026, 8:05 AM EST - 2 months ago

Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office

Dec 29, 2025, 4:05 PM EST - 3 months ago

Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 24, 2025, 8:00 AM EST - 3 months ago

Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 4, 2025, 8:00 AM EST - 4 months ago

A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity

Nov 14, 2025, 4:05 PM EST - 5 months ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Oct 2, 2025, 8:00 AM EDT - 6 months ago

Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office

Sep 17, 2025, 1:00 AM EDT - 7 months ago

Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025

Sep 16, 2025, 8:35 AM EDT - 7 months ago

Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th

Sep 10, 2025, 8:00 AM EDT - 7 months ago

Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments

Aug 13, 2025, 5:00 PM EDT - 8 months ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Jul 8, 2025, 8:00 AM EDT - 9 months ago

Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

May 14, 2025, 9:00 AM EDT - 11 months ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 15, 2025, 8:30 AM EDT - 1 year ago

Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

Mar 27, 2025, 8:15 PM EDT - 1 year ago

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Mar 27, 2025, 10:21 AM EDT - 1 year ago

Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne

Mar 27, 2025, 9:57 AM EDT - 1 year ago

Dermata Therapeutics Shares Surge on Positive Acne Treatment Study

Mar 27, 2025, 8:00 AM EDT - 1 year ago

BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

Mar 17, 2025, 4:16 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

Mar 4, 2025, 8:03 AM EST - 1 year ago

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

Feb 25, 2025, 7:58 AM EST - 1 year ago

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

Jan 29, 2025, 4:05 PM EST - 1 year ago

Dermata to Present on BioPub on January 31, 2025

Jan 28, 2025, 4:05 PM EST - 1 year ago

Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment

Jan 23, 2025, 4:15 PM EST - 1 year ago

Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 22, 2025, 8:00 AM EST - 1 year ago

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 21, 2025, 8:00 AM EST - 1 year ago

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

Dec 16, 2024, 9:00 AM EST - 1 year ago

Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

Dec 10, 2024, 9:00 AM EST - 1 year ago

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

Dec 3, 2024, 9:00 AM EST - 1 year ago

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Nov 13, 2024, 4:15 PM EST - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Nov 11, 2024, 8:35 AM EST - 1 year ago

Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024

Oct 8, 2024, 4:15 PM EDT - 1 year ago

Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024

Sep 17, 2024, 5:15 PM EDT - 1 year ago

Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 16, 2024, 9:00 PM EDT - 1 year ago

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 5, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Jul 17, 2024, 9:00 AM EDT - 1 year ago

Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

May 17, 2024, 8:30 AM EDT - 2 years ago

Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

May 15, 2024, 4:05 PM EDT - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Mar 27, 2024, 4:05 PM EDT - 2 years ago

Dermata to Present at the Emerging Growth Conference on April 3, 2024

Mar 21, 2024, 4:05 PM EDT - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results

Feb 1, 2024, 9:00 AM EST - 2 years ago

Dermata to Present at the Emerging Growth Conference on February 7, 2024

Jan 4, 2024, 4:05 PM EST - 2 years ago

Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis

Dec 20, 2023, 4:05 PM EST - 2 years ago

Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Nov 16, 2023, 1:30 PM EST - 2 years ago

Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Nov 16, 2023, 8:00 AM EST - 2 years ago

Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols

Guestthatrader Apr. 4 at 6:07 PM

$DRMA where everyone at check in

0 · Reply

focafoca99 Apr. 2 at 7:52 PM

$DRMA Australia accepted its patent application covering the use of its Bioneedle Delivery System with topical dermal fillers.

0 · Reply

brallt Apr. 2 at 1:11 PM

$DRMA 👀 Another step in the right direction to product release. Buy the Rumor Sell the News.

0 · Reply

David_M_ Apr. 2 at 12:40 PM

$DRMA https://www.stocktitan.net/news/DRMA/dermata-receives-notice-of-acceptance-of-australian-patent-wz0p6wyu8dva.html

0 · Reply

Stock_Catcher Apr. 2 at 12:30 PM

$DRMA Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System

0 · Reply

brallt Apr. 1 at 1:48 PM

0 · Reply

SwingNow Apr. 1 at 1:06 PM

$DRMA is under naked shorting by Maxim group, the moment it break the dt they came out lowering target price

0 · Reply

Guestthatrader Mar. 31 at 7:10 PM

$DRMA one of these things is imminent acquisition partnership licensing agreements or strait buy outright not hype rumors just facts

1 · Reply

Guestthatrader Mar. 31 at 12:08 PM

$DRMA this is severely undervalued should not be trading like this

1 · Reply

Guestthatrader Mar. 31 at 2:28 AM

0 · Reply

SwingNow Mar. 30 at 11:21 PM

$DRMA buying here

0 · Reply

Reacting Mar. 30 at 9:54 PM

$DRMA i think it should have news i hope

0 · Reply

Zero11 Mar. 30 at 3:27 PM

$DRMA back in 1.11

0 · Reply

Guestthatrader Mar. 30 at 1:33 PM

$DRMA is this a run today earnings report was bullish

1 · Reply

CatRocks Mar. 30 at 11:13 AM

$DKNG $SMCI $TSLA $DRMA $AAPL bot account

0 · Reply

ChartingMasters Mar. 30 at 8:01 AM

$DKNG $SMCI $TSLA $DRMA xp

0 · Reply

OwlKing Mar. 29 at 7:50 PM

$SVRN $RMSG $PLYX $DRMA >/>/

0 · Reply

David_M_ Mar. 27 at 8:10 PM

$DRMA I'm back in!

2 · Reply

princedazzler Mar. 27 at 8:06 PM

$DRMA Stop wasting your time on this POS scam stock

1 · Reply

inthebay Mar. 27 at 4:24 PM

$DRMA we get fucking hammered. three times i’ve seen this jump.

1 · Reply

Kirubin Mar. 27 at 4:02 PM

$DRMA 🥶☠️☠️☠️☠️☠️🤣🐏🐑🐏🐑🤣🤣

0 · Reply

Yiota Mar. 27 at 9:58 AM

$DRMA Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025 Dermata Therapeutics - Dermata announced a strategic pivot to develop and commercialize direct-to-consumer ("DTC") skincare products under the brand name Tome - - Dermata plans to launch its first DTC product, our Foundational Treatment, a once-weekly mask to support a skin renewal, in the middle of 2026 - - Raised $4.125 million in gross proceeds from a private placement financing in December 2025, including participation from Dermata's Chief Executive Officer, Chief Financial Officer, and a member of the Company's management - https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/dermata-therapeutics-provides-corporate-update-and-reports-financial-1152400

0 · Reply

Market Cap	3.66M
Revenue (ttm)	0.00
Net Income (ttm)	-7.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	158,800
Avg Vol	2,461,972
Day's Range	N/A - N/A
Shares Out	2.84M
Stochastic %K	32%
Beta	0.50
Analysts	Strong Sell
Price Target	$4.00